Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
Eli Lilly and Company has announced that a total of 31 abstracts will be presented at the 49(th) European Association for the Study of Diabetes Annual Meeting in Barcelona, 23–27 September. In seven presentations, Lilly will share Phase III data for dulaglutide, its investigational GLP-1 receptor agonist, and Phase II data for LY2605541, its investigational novel basal insulin analog.
Seventeen abstracts will be presented by Boehringer Ingelheim on behalf of the Alliance with Lilly.
Lilly will present an additional seven abstracts, including research from its early-stage pipeline. Lilly's pipeline comprises nearly a dozen potential new medicines for the treatment of diabetes and its related conditions, encompassing both large and small molecules, and targeting a variety of mechanisms.
Following are details on some of the presentations from Lilly's late-stage pipeline.
Dulaglutide Data
Six dulaglutide abstracts will be presented, including efficacy, safety and health outcomes data from the Phase III programme. One of these abstracts will be given as an oral presentation. Details for the presentations are as follows:
• Tuesday, 24 September 2013, 10:45–12:15 CEST, Oral Presentation
• Efficacy and safety of dulaglutide versus metformin in type 2 diabetes
(AWARD-3) (Santiago Tofe Povedano) [Presentation 4]
• Tuesday, 24 September 2013, 13:45–14:45 CEST, General Poster Session
• Dose-finding results in an adaptive trial of dulaglutide combined
with metformin in type 2 diabetes (AWARD-5) (Zachary Skrivanek)
[Poster No. 1003]
• Thursday, 26 September 2013, 13:45–14:45 CEST, General Poster Session
• Efficacy and safety of dulaglutide versus placebo and exenatide in
type 2 diabetes (AWARD-1) (Carol Wysham) [Poster No. 919]
• Safety and efficacy of dulaglutide vs sitagliptin after 104 weeks in
type 2 diabetes (AWARD-5) (Bruno Guerci) [Poster No. 920]
• Efficacy and safety of dulaglutide vs sitagliptin after 52 weeks in
type 2 diabetes (AWARD-5) (Michael Nauck) [Poster No. 921]
• Patient-reported outcomes with dulaglutide, exenatide, or placebo
(AWARD-1) (Kate Van Brunt) [Poster No. 985]
Novel Basal Insulin Analog (LY2605541) Data
One Phase II abstract will be presented for LY2605541. Details for the presentation are as follows:
• Thursday, 26 September 2013, 12:30–13:30 CEST, General Poster Session
• LY2605541 exhibits a flatter glucodynamic profile than insulin
glargine at steady state in subjects with type 1 diabetes (Linda
Morrow) [Poster No. 1030].
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance